Roche Wins EU Approval for Susvimo in Wet AMD
Basel, Switzerland, September 21, 2026 Roche has announced that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL) for...
Wet AMD
Advertisement
Ocular Therapeutix Advances AXPAXLI Toward Wet AMD NDA
BEDFORD, Mass. — September 15, 2026 Ocular Therapeutix, Inc. announced the successful completion of its Pre-New Drug Application (Pre-NDA)...
Eyconis, Inc. Begins First-in-Human EYC-0305 Trial in Wet AMD
REDWOOD CITY, Calif., August 18, 2026 Eyconis, Inc. announced the initiation of OVERTURE, its first-in-human Phase 1b/2a clinical trial...
Outlook Therapeutics Secures FDA Approval for LYTENAVA™
ISELIN, N.J., July 24, 2026 Outlook Therapeutics has achieved a major regulatory milestone after the U.S. Food and Drug...
Roche’s Susvimo Receives Positive CHMP Opinion for EU Approval
BASEL, Switzerland, July 24, 2026 Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use...
Advertisements
Samsung Bioepis and Harrow Strengthen SB11 Clinical Evidence
INCHEON, South Korea & NASHVILLE, Tenn., July 20, 2026 Samsung Bioepis Co., Ltd. and Harrow, Inc. have presented positive...
Harrow Highlights New IHEEZO and BYOOVIZ Clinical Evidence at ASRS 2026
NASHVILLE, Tenn., July 20, 2026 Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150
EMERYVILLE, Calif., July 18, 2026 4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical...
REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
Advertisement
